Castrate Resistant Prostate Cancer (CRPC)
Showing 1 - 25 of >10,000
Castrate-Resistant Prostate Cancer Trial in Shanghai (LIGHT-PSMA-CART cells)
Suspended
- Castrate-Resistant Prostate Cancer
- LIGHT-PSMA-CART cells
-
Shanghai, Shanghai, ChinaChanghai Hospital
Jan 25, 2023
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in Detroit,
Active, not recruiting
- Castration Levels of Testosterone
- +4 more
-
Detroit, Michigan
- +1 more
Aug 30, 2022
Prostate Cancer Recurrent Trial in Indianapolis (Low protein diet, Control protein diet)
Completed
- Prostate Cancer Recurrent
- Low protein diet
- Control protein diet
-
Indianapolis, Indiana
- +1 more
Mar 25, 2021
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer Trial in Detroit (docetaxel,
Completed
- Adenocarcinoma of the Prostate
- +3 more
- docetaxel
- +2 more
-
Detroit, MichiganBarbara Ann Karmanos Cancer Institute
Mar 2, 2021
Metastatic Castrate Resistant Prostate Cancer Trial in Boston, Detroit, Columbus (Docetaxel, Radium 223)
Recruiting
- Metastatic Castrate Resistant Prostate Cancer
- Docetaxel
- Radium 223
-
Boston, Massachusetts
- +3 more
Feb 22, 2022
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in United
Recruiting
- Hormone-Resistant Prostate Cancer
- +3 more
-
Ann Arbor, Michigan
- +3 more
Feb 2, 2023
Metastatic Castrate-resistant Prostate (CRPC) Cancer Trial in Villejuif (ODM-201, Enzalutamide)
Unknown status
- Metastatic Castrate-resistant Prostate (CRPC) Cancer
-
Villejuif, Val De Marne, FranceGustave Roussy
Feb 23, 2021
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial (Sipuleucel-T Injection)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sipuleucel-T Injection
- (no location specified)
Nov 10, 2023
Castrate-Resistant Prostate Cancer Trial in Hangzhou (PD1-PSMA-CART cells)
Recruiting
- Castrate-Resistant Prostate Cancer
- PD1-PSMA-CART cells
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University
Feb 26, 2022
Castrate-resistant Prostate Cancer (CRPC) Trial in United States (tomivosertib (eFT508))
Completed
- Castrate-resistant Prostate Cancer (CRPC)
- tomivosertib (eFT508)
-
New Haven, Connecticut
- +9 more
Apr 27, 2020
Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Trial (TmPSMA-02 CAR T Cells)
Not yet recruiting
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
- TmPSMA-02 CAR T Cells
- (no location specified)
Sep 13, 2023
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Baltimore
Recruiting
- Prostate Cancer
- +2 more
- Testosterone Undecanoate
- Enzalutamide
-
Baltimore, MarylandJohns Hopkins Hospital
May 6, 2022
Metastatic Castration-Resistant Prostate Cancer (mCRPC) Trial ([177Lu]Lu-PSMA-617, ARDT, [68Ga]Ga-PSMA-11)
Not yet recruiting
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [177Lu]Lu-PSMA-617
- +3 more
- (no location specified)
Jan 23, 2023
Melanoma, Prostate Cancer, Renal Cancer Trial in Providence (Naltrexone)
Terminated
- Melanoma
- +2 more
-
Providence, Rhode IslandMiriam Hospital
Feb 23, 2022
Health-related Quality of Life, Psychological Distress and
Completed
- Castrate Resistant Prostate Cancer
- Bone Metastases
-
's-Hertogenbosch, Netherlands
- +10 more
Jul 29, 2021
Metastasis Castration Resistant Prostate Cancer(mCRPC) Trial (HS-20093)
Not yet recruiting
- Metastasis Castration Resistant Prostate Cancer(mCRPC)
- (no location specified)
Aug 14, 2023
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco
Not yet recruiting
- Castrate Resistant Prostate Cancer
- +3 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Mar 1, 2023
Prostate Cancer Trial in Houston (Alpharadin)
Completed
- Prostate Cancer
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 16, 2022
Prostatic Tumors, Castration-Resistant Trial (64Cu-SAR-BBN, 67Cu-SAR-BBN)
Not yet recruiting
- Prostatic Neoplasms
- Castration-Resistant
- (no location specified)
Dec 1, 2022
Metastatic Castration-resistant Prostate Cancer, mCRPC Trial in Seoul ([177Lu]Ludotadipep)
Recruiting
- Metastatic Castration-resistant Prostate Cancer, mCRPC
-
Seoul, Korea, Republic ofThe Catholic University of Korea, Seoul, St, Mary's Hospital, 22
Dec 8, 2022
Castration-resistant Prostate Cancer Trial in Wuxi (Polaprezinc, Abiraterone)
Enrolling by invitation
- Castration-resistant Prostate Cancer
-
Wuxi, Jiangsu, ChinaJiangnan University
Sep 18, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Apalutamide, Biopsy, Biospecimen Collection)
Not yet recruiting
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Apalutamide
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jul 20, 2023
Prostate Cancer Trial in Sapporo city, Kanazawa-city (177Lu-PSMA-617, 68Ga-PSMA-11, Best supportive/best standard of care)
Recruiting
- Prostate Cancer
- 177Lu-PSMA-617
- +2 more
-
Kashiwa, Chiba, Japan
- +6 more
Jan 23, 2023